Telo Genomics Appoints Baechler Executive Chairman of The Board of Directors
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) has announced the appointment of Guido Baechler as Executive Chairman. Baechler, who joined the board in 2019 and became Chairman in 2020, brings over 30 years of life sciences and medical diagnostics experience, including nearly two decades at Roche Diagnostics.
In his expanded role, Baechler will provide active strategic leadership alongside founder Dr. Sabine Mai to advance the company's machine-learning-driven 3D Telomere platform in oncology, focusing on multiple myeloma and prostate cancer. The company's TeloView® platform is designed for clinical laboratory integration, with their CLIA/CAP certified Toronto facility supporting drug development and patient care.
The company also announced board member John Meekison's departure and the non-renewal of former President Sherif Louis's consulting arrangement. Additionally, Telo Genomics has granted 2,460,000 stock options to insiders, employees, and consultants at an exercise price of $0.15 per share with varying terms.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) ha annunciato la nomina di Guido Baechler come Presidente Esecutivo. Baechler, che è entrato a far parte del consiglio nel 2019 ed è diventato Presidente nel 2020, porta con sé oltre 30 anni di esperienza nelle scienze della vita e nella diagnostica medica, inclusi quasi due decenni presso Roche Diagnostics.
Nel suo ruolo ampliato, Baechler fornirà una leadership strategica attiva insieme al fondatore Dr. Sabine Mai per promuovere la piattaforma 3D Telomere basata su machine learning in oncologia, concentrandosi sul mieloma multiplo e sul cancro alla prostata. La piattaforma TeloView® dell'azienda è progettata per l'integrazione nei laboratori clinici, con il loro impianto di Toronto certificato CLIA/CAP che supporta lo sviluppo di farmaci e la cura dei pazienti.
L'azienda ha anche annunciato la partenza del membro del consiglio John Meekison e la non rinnovazione dell'accordo di consulenza dell'ex Presidente Sherif Louis. Inoltre, Telo Genomics ha concesso 2.460.000 opzioni su azioni a insider, dipendenti e consulenti a un prezzo di esercizio di $0,15 per azione con termini variabili.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) ha anunciado el nombramiento de Guido Baechler como Presidente Ejecutivo. Baechler, quien se unió a la junta en 2019 y se convirtió en Presidente en 2020, aporta más de 30 años de experiencia en ciencias de la vida y diagnósticos médicos, incluidos casi dos décadas en Roche Diagnostics.
En su rol ampliado, Baechler proporcionará liderazgo estratégico activo junto al fundador Dr. Sabine Mai para avanzar en la plataforma 3D Telomere impulsada por machine learning en oncología, enfocándose en el mieloma múltiple y el cáncer de próstata. La plataforma TeloView® de la empresa está diseñada para la integración en laboratorios clínicos, con su instalación en Toronto, certificada por CLIA/CAP, que apoya el desarrollo de medicamentos y la atención al paciente.
La empresa también anunció la salida del miembro de la junta John Meekison y la no renovación del acuerdo de consultoría del ex Presidente Sherif Louis. Además, Telo Genomics ha otorgado 2,460,000 opciones sobre acciones a personas internas, empleados y consultores a un precio de ejercicio de $0.15 por acción con términos variables.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF)는 Guido Baechler를 집행 의장으로 임명했다고 발표했습니다. Baechler는 2019년에 이사회에 합류하고 2020년에 의장이 되었으며, 생명 과학 및 의료 진단 분야에서 30년 이상의 경험을 보유하고 있으며, Roche Diagnostics에서 거의 20년을 근무했습니다.
확대된 역할에서 Baechler는 창립자인 Dr. Sabine Mai와 함께 기계 학습 기반 3D 텔로미어 플랫폼을 암 분야에서 발전시키기 위한 전략적 리더십을 제공할 것입니다. 이는 다발성 골수종 및 전립선암에 중점을 두고 있습니다. 회사의 TeloView® 플랫폼은 임상 실험실 통합을 위해 설계되었으며, CLIA/CAP 인증을 받은 토론토 시설이 약물 개발 및 환자 치료를 지원합니다.
회사는 또한 이사 John Meekison의 퇴사와 전 회장 Sherif Louis의 컨설팅 계약 비갱신을 발표했습니다. 추가로, Telo Genomics는 내부자, 직원 및 컨설턴트에게 주당 $0.15의 행사 가격으로 2,460,000개의 주식 옵션을 부여했습니다.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) a annoncé la nomination de Guido Baechler en tant que Président Exécutif. Baechler, qui a rejoint le conseil d'administration en 2019 et est devenu Président en 2020, apporte plus de 30 ans d'expérience dans les sciences de la vie et le diagnostic médical, dont près de deux décennies chez Roche Diagnostics.
Dans son rôle élargi, Baechler fournira un leadership stratégique actif aux côtés du fondateur Dr. Sabine Mai pour faire avancer la plateforme 3D Telomere alimentée par l'apprentissage automatique en oncologie, en se concentrant sur le myélome multiple et le cancer de la prostate. La plateforme TeloView® de l'entreprise est conçue pour l'intégration dans les laboratoires cliniques, avec leur installation à Toronto, certifiée CLIA/CAP, soutenant le développement de médicaments et les soins aux patients.
L'entreprise a également annoncé le départ du membre du conseil John Meekison et la non-renouvellement de l'accord de consultation de l'ancien Président Sherif Louis. De plus, Telo Genomics a accordé 2 460 000 options d'achat d'actions à des initiés, employés et consultants à un prix d'exercice de 0,15 $ par action avec des conditions variables.
Telo Genomics (TSXV: TELO, OTCQB: TDSGF) hat die Ernennung von Guido Baechler zum Executive Chairman bekannt gegeben. Baechler, der 2019 in den Vorstand eintrat und 2020 Vorsitzender wurde, bringt über 30 Jahre Erfahrung in den Lebenswissenschaften und der medizinischen Diagnostik mit, darunter fast zwei Jahrzehnte bei Roche Diagnostics.
In seiner erweiterten Rolle wird Baechler zusammen mit der Gründerin Dr. Sabine Mai aktiv strategische Führung bieten, um die maschinenlerngetriebene 3D-Telomere-Plattform in der Onkologie voranzutreiben, mit einem Fokus auf multiples Myelom und Prostatakrebs. Die TeloView®-Plattform des Unternehmens ist für die Integration in klinische Labore konzipiert, wobei die CLIA/CAP-zertifizierte Einrichtung in Toronto die Arzneimittelentwicklung und Patientenversorgung unterstützt.
Das Unternehmen gab außerdem den Rücktritt des Vorstandsmitglieds John Meekison und die Nichtverlängerung des Beratungsvertrags des ehemaligen Präsidenten Sherif Louis bekannt. Darüber hinaus hat Telo Genomics 2.460.000 Aktienoptionen an Insider, Mitarbeiter und Berater zu einem Ausübungspreis von 0,15 $ pro Aktie mit unterschiedlichen Bedingungen gewährt.
- Appointment of experienced executive (30+ years) from Roche Diagnostics as Executive Chairman
- CLIA/CAP certified testing facility operational in Toronto
- Platform shows clinical utility for multiple cancer types
- TeloView platform ready for clinical laboratory integration
- Departure of board member and former President indicates management restructuring
- Significant stock option grants (2.46M shares) may lead to potential dilution
Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce Mr. Guido Baechler, has assumed the role of Executive Chairman. In his expanded role, Mr. Baechler will provide more active strategic leadership, working closely with the company's founder Dr. Sabine Mai and with the executive team to further advance Telo Genomics' groundbreaking machine-learning (ML)-driven 3D Telomere platform in oncology, which is currently focused on multiple myeloma and prostate cancer.
Mr. Baechler joined Telo Genomics' Board of Directors on February 28, 2019, as an independent director and was appointed Chairman on May 6, 2020. He brings over 30 years of leadership experience in the life sciences and medical diagnostics industries, with a strong track record of driving growth and innovation. Prior to joining Telo Genomics, Mr. Baechler spent nearly two decades at Roche Diagnostics, the world's leading diagnostics company, where he held various senior leadership roles across Europe and North America. His deep expertise in advancing cutting-edge diagnostic technologies and commercializing clinical solutions positions him well, to help guide Telo Genomics through its next phase of growth and commercialization.
"I am excited to become more involved in leading the advancement of Telo Genomics' innovative tests from clinical research to commercial products," said Guido Baechler, executive Chairman of Telo Genomics. "With Dr. Mai's vast body of research using telomeres to measure genomic instability, our TELO platform has been proven to show clinical utility for several malignant diseases and because of its inherent sensitivity, it is a provocative approach to the market for liquid biopsies for early detection and monitoring of minimal residual disease (MRD). Specifically, we are excited about using our tests to provide actionable results for multiple myeloma, Hodgkin's disease and prostate cancer. We see significant additional commercial opportunities based on our platform technology. Our TeloView® platform is engineered for seamless integration into clinical laboratories, while our CLIA/CAP certified Toronto-based testing facility is well-positioned to provide high-impact precision medicine data to pharma and biotech partners, supporting drug development and patient care. I also wanted to take this opportunity to report that John Meekison has left the board of Telo. John was an extremely valuable member of our team and on behalf of the board, I would like to thank him for his commitment to the Company and efforts on our behalf."
The Company also reports that the consulting arrangement with Sherif Louis, the former President of the Company, has not been renewed. Mr. Louis' duties will be assumed on an interim basis by members of the senior management team under the guidance of Mr. Baechler.
Pursuant to the Company's 2022 stock option plan, the Company announces that it has granted 2,150,000 options to certain insiders of the Company, entitling the holder thereof to acquire one common share of the Company at an exercise price of
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
Guido Baechler
Executive Chairman
416-673-8487
info@telodx.com
MaRS Centre, South Tower
101 College Street, Suite 200
Toronto, ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the issuance of Shares to THA and the terms thereof, and the Company's receipt of TSXV acceptance, are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244208
FAQ
What is the significance of Guido Baechler's appointment as Executive Chairman for TDSGF?
How many stock options did TDSGF grant and at what price in March 2025?
What are the main focus areas for TDSGF's TeloView platform?
What recent management changes occurred at TDSGF besides Baechler's appointment?
